Our research focuses on understanding the molecular basis of autoimmune conditions in haematology, particularly immune thrombocytopenia (ITP), a condition leading to premature destruction of platelets.
We combine genetic and genomic analysis of individuals with extreme phenotypes, CRISPR-based in vitro functional validation, and parallel ‘omic' approaches to define novel pathways regulating autoimmunity (eg Afzaku B et al Nat Immunol 2017 18:813-823).
et al., 2023, A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia., Blood Adv, Vol:7, Pages:396-405
et al., 2023, The role of CD8+ T cell clones in immune thrombocytopenia., Blood
et al., 2022, Transcriptional reprogramming from innate immune functions to a pro-thrombotic signature by monocytes in COVID-19, Nature Communications, Vol:13, ISSN:2041-1723, Pages:1-17
et al., 2022, The effect of TRV027 on coagulation in COVID 19: A pilot randomized, placebo-controlled controlled trial, British Journal of Clinical Pharmacology, ISSN:0306-5251
et al., 2022, Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK), 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), AMER SOC HEMATOLOGY, Pages:2678-2680, ISSN:0006-4971